Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species

U Karakus, D Sahin, PRE Mittl, P Mooij… - Science translational …, 2020 - science.org
Stimulation of regulatory T (Treg) cells holds great promise for the treatment of autoimmune,
chronic inflammatory, and certain metabolic diseases. Recent clinical trials with low-dose …

A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism

E Trotta, PH Bessette, SL Silveria, LK Ely, KM Jude… - Nature medicine, 2018 - nature.com
Abstract Interleukin-2 (IL-2) has been shown to suppress immune pathologies by
preferentially expanding regulatory T cells (Tregs). However, this therapy has been limited …

Targeting IL-2: an unexpected effect in treating immunological diseases

C Ye, D Brand, SG Zheng - Signal transduction and targeted therapy, 2018 - nature.com
Regulatory T cells (Treg) play a crucial role in maintaining immune homeostasis since Treg
dysfunction in both animals and humans is associated with multi-organ autoimmune and …

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

D VanDyke, M Iglesias, J Tomala, A Young, J Smith… - Cell reports, 2022 - cell.com
Summary Low-dose human interleukin-2 (hIL-2) treatment is used clinically to treat
autoimmune disorders due to the cytokine's preferential expansion of immunosuppressive …

[HTML][HTML] Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms

JB Spangler, J Tomala, VC Luca, KM Jude, S Dong… - Immunity, 2015 - cell.com
Summary Interleukin-2 (IL-2) is a pleiotropic cytokine that regulates immune cell
homeostasis and has been used to treat a range of disorders including cancer and …

Engineering a single-agent cytokine/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy

JB Spangler, E Trotta, J Tomala, A Peck… - The Journal of …, 2018 - journals.aai.org
IL-2 has been used to treat diseases ranging from cancer to autoimmune disorders, but its
concurrent immunostimulatory and immunosuppressive effects hinder efficacy. IL-2 …

IL-2/CD25: a long-acting fusion protein that promotes immune tolerance by selectively targeting the IL-2 receptor on regulatory T cells

NC Ward, A Yu, A Moro, Y Ban, X Chen… - The Journal of …, 2018 - journals.aai.org
Low-dose IL-2 represents an immunotherapy to selectively expand regulatory T cells (Tregs)
to promote tolerance in patients with autoimmunity. In this article, we show that a fusion …

Anti‐CD 25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis

DJ Huss, AF Pellerin, BP Collette, AK Kannan… - …, 2016 - Wiley Online Library
Summary Interleukin‐2 (IL‐2) is a critical regulator of immune homeostasis through its non‐
redundant role in regulatory T (Treg) cell biology. There is major interest in therapeutic …

IL-2 immunotherapy for targeting regulatory T cells in autoimmunity

V Lykhopiy, V Malviya, S Humblet-Baron… - Genes & …, 2023 - nature.com
FOXP3+ regulatory T cells (Treg) are indispensable for immune homoeostasis and for the
prevention of autoimmune diseases. Interleukin-2 (IL-2) signalling is critical in all aspects of …

Application of IL-2 therapy to target T regulatory cell function

EM Shevach - Trends in immunology, 2012 - cell.com
Interleukin-2 (IL-2) was originally discovered as a growth factor for activated T cells in vitro.
IL-2 promotes CD8+ T cell growth and differentiation in vivo, but has little effect on CD4+ T …